Scientists search for hidden clues in blood to improve myasthenia gravis treatment
NCT ID NCT07337395
Summary
This study aims to understand how the drug ravulizumab affects people with generalized myasthenia gravis by tracking changes in their blood proteins over time. Researchers will follow 24 adult patients for 26 weeks, collecting blood samples to identify proteins linked to treatment response and potential nerve-muscle junction repair. The goal is to find better ways to monitor treatment effectiveness and guide future therapies, not to test a new cure.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS GENERALISED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fondazione Policlinico Universitario A. Gemelli IRCCS
Roma, 00168, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.